Program
S-892216
A development code. Also written as “S-892216-PO” and “S-892216-LAI”.
Its studies are mostly in COVID-19 · Renal Insufficiency, led by Shionogi.
Furthest: phase 2, since Apr 9, 20254 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogi | 41 open or running | phase 2since Apr 9, 2025 | Dec 20, 2024 | Jun 30, 2028phase 1 · NCT07093580 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2024First study: phase 1 study in COVID-19First studyNCT06751017 · 16 enrolled · United States
- Apr 9, 2025Phase 2 study in COVID-19NCT06928051 · 282 enrolled · United States, Japan
- Jul 23, 2025Phase 1 study in COVID-19NCT07093580 · 128 planned · United States
- Oct 14, 2025Phase 1 study in Renal InsufficiencyNCT07217886 · 24 enrolled · United States
Ahead
- Jun 30, 2028Primary completion: phase 1 study in COVID-19NCT07093580
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07217886Renal Insufficiency · United States | 1 | Completed | Feb 13, 2026 | 24 |
| NCT07093580COVID-19 · United States | 1 | Recruiting | Jun 30, 2028 | 128 |
| NCT06928051COVID-19 · United States, Japan | 2 | Completed | Sep 22, 2025 | 282 |
| NCT06751017COVID-19 · United States | 1 | Completed | Feb 24, 2025 | 16 |
How it is read
Names in the registry
- “S-892216”, 2 entries
- “S-892216-PO”, 1 entry
- “S-892216-LAI”, 1 entry
Codes read as this program: S892216.
Conditions, from the studies’ own filings
- COVID-19, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.